Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) and Cisplatin as First-Line Therapy for Advanced Gastric Cancer

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Hoffmann-La Roche
ClinicalTrials.gov Identifier:
NCT00887822
First received: April 22, 2009
Last updated: November 24, 2014
Last verified: November 2014
  Purpose

This 2 arm study will compare the efficacy and safety of Avastin versus placebo, in combination with Xeloda and cisplatin, in patients who have received no prio r treatment for advanced or metastatic gastric cancer. Patients will be randomiz ed to receive either Avastin 7.5mg/kg iv or placebo iv, in combination with Xelo da 1000mg/m2 po bid on days 1-14 of each 3 week cycle, and cisplatin 80mg/m2 eve ry 3 weeks. The anticipated time on study treatment is until disease progression

, and the target sample size is 100-500 individuals.


Condition Intervention Phase
Gastric Cancer
Drug: Placebo
Drug: bevacizumab [Avastin]
Drug: capecitabine [Xeloda]
Drug: cisplatin
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Double-blind, Randomised, Multicenter, Phase III Study of Bevacizumab in Combination With Capecitabine and Cisplatin Versus Placebo in Combination With Capecitabine and Cisplatin, as First-line Therapy in Chinese Patients With Advanced Gastric Cancer.

Resource links provided by NLM:


Further study details as provided by Hoffmann-La Roche:

Primary Outcome Measures:
  • Overall survival [ Time Frame: Event driven; monitored throughout study ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Progression-free survival; time to progression; overall response rate; duration of response [ Time Frame: Event driven; monitored throughout study ] [ Designated as safety issue: No ]
  • Adverse events; laboratory parameters [ Time Frame: Throughout study; at each clinic visit ] [ Designated as safety issue: No ]

Enrollment: 202
Study Start Date: March 2009
Estimated Study Completion Date: December 2014
Estimated Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Drug: bevacizumab [Avastin]
7.5mg/kg every 3 weeks until disease progression
Drug: capecitabine [Xeloda]
1000mg/m2 po bid on days 1-14 of each 3 week cycle until disease progression
Drug: cisplatin
80mg/m2 iv every 3 weeks for a maximum of 6 cycles, or until disease progression
Placebo Comparator: 2 Drug: Placebo
iv every 3 weeks until disease progression
Drug: capecitabine [Xeloda]
1000mg/m2 po bid on days 1-14 of each 3 week cycle until disease progression
Drug: cisplatin
80mg/m2 iv every 3 weeks for a maximum of 6 cycles, or until disease progression

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • adult patients, >=18 years of age;
  • histologically confirmed cancer of the stomach or gastro-oesophageal junction;
  • inoperable, locally advanced or metastatic disease, not amenable to curative therapy;
  • ECOG PS of 0,1 or 2.

Exclusion Criteria:

  • previous chemotherapy for locally advanced or metastatic gastric cancer;
  • previous platinum or anti-angiogenic therapy;
  • radiotherapy within 28 days of randomisation;
  • evidence of CNS metastasis at baseline.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00887822

Locations
China
Beijing, China, 100142
Beijing, China, 100071
Beijing, China, 100021
Beijing, China, 100853
ChongQing, China, 400042
Guangzhou, China, 510060
Hangzhou, China, 310016
Nanjing, China, 210029
Nanjing, China, 210002
Shanghai, China, 200032
Shanghai, China, 200080
Shantou, China, 515041
Shenyang, China, 110001
Wuhan, China, 430030
Sponsors and Collaborators
Hoffmann-La Roche
Investigators
Study Director: Clinical Trials Hoffmann-La Roche
  More Information

No publications provided

Responsible Party: Hoffmann-La Roche
ClinicalTrials.gov Identifier: NCT00887822     History of Changes
Other Study ID Numbers: ML22367
Study First Received: April 22, 2009
Last Updated: November 24, 2014
Health Authority: China: Ministry of Health

Additional relevant MeSH terms:
Stomach Neoplasms
Digestive System Diseases
Digestive System Neoplasms
Gastrointestinal Diseases
Gastrointestinal Neoplasms
Neoplasms
Neoplasms by Site
Stomach Diseases
Bevacizumab
Capecitabine
Cisplatin
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Antimetabolites
Antimetabolites, Antineoplastic
Antineoplastic Agents
Growth Inhibitors
Growth Substances
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Radiation-Sensitizing Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on November 24, 2014